![conference banner](/images/conference-banner.jpeg)
摘要
背景: 麻黄属无患子科,俗称麻花。它主要以生产酒精饮料而闻名,据报道具有抗炎、镇痛和解热的特性。马杜卡也被报道对几种疾病有效。 目的: 本研究旨在探讨麻花甲醇提取物(Me)对人乳腺癌细胞系MCF-7和MDA-MB-468的抗癌作用和化学预防作用。 方法: 采用MTT法、己糖胺酶法和菌落形成法研究了其对MCF-7和MDA-MB-468细胞的毒性和抗增殖作用。流式细胞术和Western blot分析评价caspase 3/7的表达。用Western blot分析、荧光素酶分析和mRNA分析评价COX-2的表达。 结果: ME通过上调caspase 3/7的表达来诱导细胞凋亡,从而抑制乳腺癌细胞的增殖(P<0.0001)。我们的结果显示,随着ME浓度的增加,MCF-7和MDA-MB-468细胞中COX-2的mRNA和COX-2蛋白的表达均下降。此外,在MCF-7和MDA-MB-468细胞中还研究了ME和化疗药物紫杉醇的协同作用,发现它们比单独治疗ME或紫杉醇更有效(p<0.0001)。结果采用方差分析和皮尔逊相关分析。 结论: 所有这些实验表明,ME通过抑制COX-2在MCF-7和MDAMB-468细胞中的表达来抑制乳腺癌细胞的增殖和凋亡。这项工作进一步强调,我可能会增强紫杉醇在乳腺癌治疗的潜力。
关键词: MCF-7,MDA-MB-468,ME,COX-2,紫杉醇,AKT,NF-κB。
Current Molecular Medicine
Title:Madhuca indica Inhibits Breast Cancer Cell Proliferation by Modulating COX-2 Expression
Volume: 18 Issue: 7
关键词: MCF-7,MDA-MB-468,ME,COX-2,紫杉醇,AKT,NF-κB。
摘要: Background: Madhuca indica belongs to the family sapotaceae, commonly known as Mahua. It is primarily known for alcoholic beverage production and is reported to have anti-inflammatory, analgesic and antipyretic properties. Madhuca indica has also been reported to be effective in several diseases.
Objective: This study was undertaken to check the anticancer efficacy and chemopreventive effect of methanolic extract of Mahua flower (ME) on human breast cancer cell lines MCF-7 and MDA-MB-468.
Method: The cytotoxic and anti-proliferative effects on MCF-7 and MDA-MB-468 cells were studied by MTT, hexosaminidase and colony formation assay. Expression of caspase 3/7 was assessed by flow cytometry and western blot analysis. Expression of COX-2 was evaluated by western blot analysis, luciferase assay and mRNA analysis.
Results: ME inhibited the proliferation of breast cancer cells by inducing apoptosis through up-regulating the expression of Caspase 3/7 (P < 0.0001). Our results showed a decrease in the expression of COX-2 mRNA and COX-2 protein in both MCF-7 and MDA-MB-468 cells with an increase in ME concentration. Furthermore synergistic effect of ME and chemotherapeutic drug paclitaxel was also studied in MCF-7 and MDA-MB- 468 cells which were found to be more effective (P < 0.0001) than treatment of either ME or paclitaxel alone. Results were analyzed by ANOVA and Pearson correlation analysis.
Conclusion: All these experiments suggest that ME inhibits breast cancer cell proliferation and apoptosis by inhibiting the expression of COX-2 in MCF-7 and MDAMB- 468 cells. This work further highlighted that ME may enhance the potentiality of paclitaxel in breast cancer treatment.
Export Options
About this article
Cite this article as:
Madhuca indica Inhibits Breast Cancer Cell Proliferation by Modulating COX-2 Expression, Current Molecular Medicine 2018; 18 (7) . https://dx.doi.org/10.2174/1566524019666181212100808
DOI https://dx.doi.org/10.2174/1566524019666181212100808 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>In-silico</i> Evaluation of Novel Honokiol Derivatives against Breast Cancer Target
Protein <i>LKB1</i>
Anti-Cancer Agents in Medicinal Chemistry The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Interrelated Roles for the Aryl Hydrocarbon Receptor and Hypoxia Inducible Factor-1α in the Immune Response to Infection
Current Immunology Reviews (Discontinued) Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Molecular Testing and Personalized Treatment of Lung Cancer
Current Molecular Pharmacology Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
Current Pharmaceutical Biotechnology Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals